Monthly Cost Breakdown for Both Weight Loss Injections
Understanding Mounjaro vs Wegovy Dose Equivalent Pricing Structures
When comparing Mounjaro vs Wegovy dose equivalent costs, it's essential to understand that these prescription-only medicines follow different escalation schedules. Wegovy escalates through five distinct doses over 16 weeks: 0.25mg (£79.99), 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), and 2.4mg maintenance (£209.99). Mounjaro follows its own pathway with different dosing intervals and strengths. Neither medication allows dose skipping—the escalation protects against gastrointestinal side effects whilst optimising efficacy. Both treatments are available from EverydayMeds, and your prescriber can help determine which dosing schedule suits your individual needs and budget.
The monthly cost comparison becomes more complex because direct dose equivalency between semaglutide and tirzepatide isn't established through head-to-head trials. Wegovy's mechanism as a GLP-1 receptor agonist differs from Mounjaro's dual GIP and GLP-1 approach, meaning therapeutic equivalence cannot be determined by dose alone. UK patients should focus on each medication's individual cost structure rather than seeking precise dose equivalents. This approach ensures you budget accurately for whichever treatment your prescriber recommends based on your clinical assessment and weight management goals.
Wegovy Monthly Cost Progression and Long-Term Budgeting
Wegovy's monthly cost progression allows for predictable budgeting throughout your weight management journey. Month one begins at £79.99 with the 0.25mg starter dose using code FIRST40 for new customers. Month two increases to £94.99 for 0.5mg, followed by £99.99 for 1mg in month three. The penultimate escalation to 1.7mg costs £139.99 in month four, before reaching the maintenance 2.4mg dose at £209.99 from month five onwards. This transparent pricing structure helps you plan your annual weight management investment, with the first four months totalling £414.96 and subsequent months at the consistent maintenance rate.
For ongoing treatment, returning customers benefit from the DOSE25 discount code, ensuring competitive pricing throughout maintenance therapy. The 2.4mg maintenance dose at £209.99 monthly translates to approximately £2,519.88 annually for consistent weight management support. EverydayMeds' bundle options, such as the Ultimate Stability Trio providing three months of 2.4mg pens for £649.99, offer convenient supply management. Our GPhC-registered pharmacy (#9012878) ensures cold-chain delivery and pharmaceutical oversight for every prescription.
Clinical Evidence for Mounjaro vs Wegovy Dose Equivalent Effectiveness
The STEP clinical trial programme demonstrated Wegovy's efficacy across multiple populations and settings. In STEP 1, participants achieved an average weight reduction of approximately 15% at 68 weeks when combined with lifestyle interventions, compared to 2.4% with placebo. STEP 2 specifically evaluated patients with type 2 diabetes, showing average weight reductions of 9.6% with the 2.4mg maintenance dose. The landmark SELECT cardiovascular outcomes trial, as published by Lincoff et al., demonstrated a 20% reduction in major adverse cardiovascular events.
Mounjaro's SURMOUNT trial programme showed its own clinical profile, though direct comparison with STEP results isn't appropriate due to different trial designs and populations. When evaluating Mounjaro vs Wegovy dose equivalent options, focus on each medication's individual evidence base rather than head-to-head comparisons. Both treatments demonstrated efficacy alongside reduced-calorie diets and increased physical activity, supporting their roles in comprehensive weight management programmes under medical supervision.
How Wegovy's Mechanism Differs from Mounjaro's Dual Action
Wegovy functions as a selective GLP-1 receptor agonist, mimicking the natural hormone GLP-1 that your intestines release after eating. This mechanism reduces appetite by acting on brain centres that control hunger and satiety, promoting feelings of fullness after smaller meals. Wegovy may also slow gastric emptying, extending the duration of meal satisfaction. The once-weekly injection maintains consistent semaglutide levels, supporting appetite regulation throughout the week. Clinical assessment is required to determine if Wegovy's GLP-1-focused approach aligns with your individual weight management needs and medical history.
EverydayMeds Ordering Process for Both Weight Loss Treatments
Accessing either medication through EverydayMeds begins with our three-minute online clinical assessment, covering your medical history, current medications, and weight management goals. Our qualified prescribers review your assessment within three working days (or 24 hours with express service), ensuring safe and appropriate prescribing for your individual circumstances. Once approved, your prescription is dispensed by our GPhC-registered pharmacy and delivered via next-day cold-chain service to maintain medication integrity. This process applies to both Wegovy and Mounjaro prescriptions, with your assigned prescriber helping determine which treatment suits your clinical profile. Our clinical team remains available throughout your treatment for ongoing support and monitoring.
Storage Advantages and Practical Considerations for Dose Equivalent Planning
Wegovy offers superior storage flexibility compared to Mounjaro, particularly relevant for travel and lifestyle planning. Unopened Wegovy pens remain stable for up to 6 weeks at room temperature below 30°C, compared to Mounjaro's 21-day limit. This advantage becomes significant during holidays, business travel, or temporary accommodation changes. Both medications require refrigeration at 2-8°C for optimal storage, but Wegovy's extended room temperature stability reduces anxiety about temperature excursions. The FlexTouch pen design provides clear dose confirmation and user-friendly administration, with each pen containing exactly four weekly doses for the prescribed strength.
Unique Cost Considerations for Mounjaro vs Wegovy Dose Equivalent Treatment
Unlike other weight management comparisons, evaluating Mounjaro vs Wegovy dose equivalent costs requires understanding each medication's distinct escalation timeline and maintenance requirements. Wegovy's standardised 16-week escalation to 2.4mg maintenance provides cost predictability that many patients prefer for budget planning. The ability to use Getting Started bundles, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, can simplify early treatment logistics. Some patients benefit from Take-It-Slow bundles if their prescriber recommends extended time at lower doses to minimise side effects.
The monthly cost commitment extends beyond medication price to include clinical monitoring, dietary adjustments, and potential consultation fees. EverydayMeds includes ongoing prescriber support within our service, avoiding additional consultation charges common with other providers. This comprehensive approach to Mounjaro vs Wegovy dose equivalent evaluation ensures you receive complete clinical oversight throughout your weight management journey.
Making Your Informed Treatment Decision with Expert Support
Your prescriber will evaluate factors beyond dose equivalency when recommending between these treatments, including your medical history, previous weight management attempts, and individual response patterns. EverydayMeds' clinical team considers both efficacy profiles and monthly cost implications during your assessment, ensuring treatment recommendations align with your long-term adherence ability. Our prescribers can discuss dose equivalent considerations whilst emphasising that both Wegovy and Mounjaro are available from EverydayMeds when clinically appropriate. New customers can start their assessment today using code FIRST40, with returning customers maintaining competitive pricing through DOSE25. Contact our clinical team to begin your personalised evaluation and receive expert guidance on selecting the most suitable treatment for your weight management goals under proper medical supervision.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
